cad phaguidelines2 rev26
TRANSCRIPT
-
7/30/2019 CAD PHAguidelines2 Rev26
1/44
-
7/30/2019 CAD PHAguidelines2 Rev26
2/44
-
7/30/2019 CAD PHAguidelines2 Rev26
3/44
-
7/30/2019 CAD PHAguidelines2 Rev26
4/44
-
7/30/2019 CAD PHAguidelines2 Rev26
5/44
-
7/30/2019 CAD PHAguidelines2 Rev26
6/44
-
7/30/2019 CAD PHAguidelines2 Rev26
7/44
-
7/30/2019 CAD PHAguidelines2 Rev26
8/44
-
7/30/2019 CAD PHAguidelines2 Rev26
9/44
-
7/30/2019 CAD PHAguidelines2 Rev26
10/44
-
7/30/2019 CAD PHAguidelines2 Rev26
11/44
-
7/30/2019 CAD PHAguidelines2 Rev26
12/44
-
7/30/2019 CAD PHAguidelines2 Rev26
13/44
-
7/30/2019 CAD PHAguidelines2 Rev26
14/44
-
7/30/2019 CAD PHAguidelines2 Rev26
15/44
-
7/30/2019 CAD PHAguidelines2 Rev26
16/44
-
7/30/2019 CAD PHAguidelines2 Rev26
17/44
-
7/30/2019 CAD PHAguidelines2 Rev26
18/44
-
7/30/2019 CAD PHAguidelines2 Rev26
19/44
-
7/30/2019 CAD PHAguidelines2 Rev26
20/44
-
7/30/2019 CAD PHAguidelines2 Rev26
21/44
-
7/30/2019 CAD PHAguidelines2 Rev26
22/44
-
7/30/2019 CAD PHAguidelines2 Rev26
23/44
-
7/30/2019 CAD PHAguidelines2 Rev26
24/44
-
7/30/2019 CAD PHAguidelines2 Rev26
25/44
-
7/30/2019 CAD PHAguidelines2 Rev26
26/44
-
7/30/2019 CAD PHAguidelines2 Rev26
27/44
-
7/30/2019 CAD PHAguidelines2 Rev26
28/44
-
7/30/2019 CAD PHAguidelines2 Rev26
29/44
-
7/30/2019 CAD PHAguidelines2 Rev26
30/44
-
7/30/2019 CAD PHAguidelines2 Rev26
31/44
-
7/30/2019 CAD PHAguidelines2 Rev26
32/44
-
7/30/2019 CAD PHAguidelines2 Rev26
33/44
-
7/30/2019 CAD PHAguidelines2 Rev26
34/44
-
7/30/2019 CAD PHAguidelines2 Rev26
35/44
-
7/30/2019 CAD PHAguidelines2 Rev26
36/44
-
7/30/2019 CAD PHAguidelines2 Rev26
37/44
-
7/30/2019 CAD PHAguidelines2 Rev26
38/44
-
7/30/2019 CAD PHAguidelines2 Rev26
39/44
-
7/30/2019 CAD PHAguidelines2 Rev26
40/44
-
7/30/2019 CAD PHAguidelines2 Rev26
41/44
-
7/30/2019 CAD PHAguidelines2 Rev26
42/44
Dr. Eric Oliver D. Sison __________________________Dr. Ma. Helga F. Sta Maria ________________________Dr Eduardo L Tin Hay
none,**, **
NOTES:
-
7/30/2019 CAD PHAguidelines2 Rev26
43/44
PHA Clinical Practice Guidelines for the Management of Coronary Artery Disease 8484848484 PHA Clinical Practice Guidelines for the Management of Coronary Artery Disease 8585858585
Dr. Eduardo L. Tin Hay _________________________
Dr. Richard Nicandro R. Torres _________________________Dr. Edgar S. Tuazon _________________________Dr. Liberty O. Yaneza _________________________
PANEL OF EXPERTS
Dr. Joel M. Abanilla _________________________
Dr. Ramon F. Abarquez Jr. _________________________Dr. Maria Teresa B. Abola _________________________Dr. Homobono B. Calleja _________________________Dr. Romeo A. Divinagracia _________________________
Dr. Timothy C. Dy _________________________Dr. Loewe O. Go _________________________Dr. Kurt Glenn C. Jacoba _________________________
Dr. Saturnino P. Javier _________________________Dr. Jesus D. Jorge _________________________Dr. Isabelo V. Ongtengco, Jr. _________________________Dr. Eugene B. Reyes _________________________
Dr. Gilbert C. Vilela _________________________
, , **nonenone
*, ***, , ,**, *, , , #,**, none*, **, , none*, #,**, none*,,**,***, #,**, , #,**, , *, , **,
ACKNOWLEDGEMENTSACKNOWLEDGEMENTSACKNOWLEDGEMENTSACKNOWLEDGEMENTSACKNOWLEDGEMENTS
The CAD Guidelines Writing Committee would like to thankMyrna dela Cruz, Gene Banawa and Loreli Bulacan for their
remarkable dedication and indefatigable assistance from the time
that this PHA CAD Clinical Practice Guidelines was conceptualizedto its final publication.
Please address correspondence to the Philippine Heart Association:
E-mail: [email protected]. For more information, visit www.philheart.org.
-
7/30/2019 CAD PHAguidelines2 Rev26
44/44
PHA Clinical Practice Guidelines for the Management of Coronary Artery Disease 8686868686